Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | HPGDS | O60760 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3436406 | 0.78 | RAB9A (0.45) | HPGDSHDAC1HDAC8HDAC6NPC1 | |
| SCHEMBL3550642 | 0.76 | KMT2A (0.49) | ALDH1A1KDM4ERAB9A | |
| SCHEMBL2104811 | 0.76 | ALDH1A1 (0.73) | ALDH1A1HPGDSKDM4EPLA2G10PTPN1 | |
| SCHEMBL1785557 | 0.76 | ALDH1A1 (0.73) | ALDH1A1HPGDSKDM4EPLA2G10PTPN1 | |
| SCHEMBL26319518 | 0.76 | ALDH1A1 (0.73) | ALDH1A1HPGDSKDM4EPTPN1ACHE | |
| SCHEMBL352152 | 0.75 | HPGDS (0.73) | ALDH1A1HPGDSKDM4EPTPN1ACHE | |
| SCHEMBL3952859 | 0.75 | ALDH1A1 (0.54) | ALDH1A1HPGDSKDM4EPLA2G10ACHE | |
| SCHEMBL24136179 | 0.74 | ALDH1A1 (0.71) | ALDH1A1HPGDSKDM4EPLA2G10PTPN1 | |
| SCHEMBL3098211 | 0.74 | ALDH1A1 (1.00) | ALDH1A1HPGDSKDM4EPLA2G10PTPN1 | |
| SCHEMBL3412110 | 0.74 | ALDH1A1 (0.71) | ALDH1A1HPGDSKDM4EPLA2G10PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | GPR17, NTRK1, TRPV1 | ALDH1A1 975/4885HPGDS 2971/4885KDM4E 1834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.